Indian scientists make drug delivery breakthrough; Biodel touts clinical trial results;

> Biodel touted results from the Phase I clinical trial of its Glucagon Emergency Management (GEM) auto-reconstitution device. Release

> Indian scientists have developed a unique, targeted drug delivery system that focuses on cervical cancer cells without damaging other healthy ones. More

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.